A significant hurdle in developing reliable gene expression–based prognostic models has been the limited sample size, which can cause overfitting and false discovery. Combining data from multiple ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Neuvivo, a late-clinical stage biopharmaceutical company, today announced promising results from two groundbreaking publications on its investigational ...
Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback